{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:31:01Z","timestamp":1792740661457,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.011","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T09:40:25Z","timestamp":1555062025000},"page":"2694-2703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study"],"prefix":"10.1016","volume":"37","author":[{"given":"Geert","family":"Leroux-Roels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fien","family":"De Boever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Lien-Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherryl","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.011_b0005","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(99)80040-3","article-title":"Respiratory syncytial virus infection","volume":"354","author":"Simoes","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.04.011_b0010","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJM200106213442507","article-title":"Respiratory syncytial virus and parainfluenza virus","volume":"344","author":"Hall","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.04.011_b0015","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.04.011_b0020","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1542\/peds.113.6.1758","article-title":"Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children","volume":"113","author":"Iwane","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.04.011_b0025","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.04.011_b0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.tpb.2016.04.003","article-title":"Exploring the dynamics of respiratory syncytial virus (RSV) transmission in children","volume":"110","author":"Hogan","year":"2016","journal-title":"Theor Popul Biol"},{"key":"10.1016\/j.vaccine.2019.04.011_b0035","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.vaccine.2019.04.011_b0040","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.04.011_b0045","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/17476348.2017.1338567","article-title":"Respiratory syncytial virus: prospects for new and emerging therapeutics","volume":"11","author":"Jorquera","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.vaccine.2019.04.011_b0050","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/11531860-000000000-00000","article-title":"Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review","volume":"28","author":"Prescott","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2019.04.011_b0055","doi-asserted-by":"crossref","unstructured":"Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS, WHO RSV Vaccine Consultation Expert Group. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23-24 March 2015. Vaccine 2016;34:190\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.093.","DOI":"10.1016\/j.vaccine.2015.05.093"},{"key":"10.1016\/j.vaccine.2019.04.011_b0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2019.04.011_b0065","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix503","article-title":"An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults","volume":"216","author":"Falloon","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.011_b0070","doi-asserted-by":"crossref","unstructured":"van Drunen Littel-van den Hurk S, Watkiss ER. Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2012;2:300\u20135. https:\/\/doi.org\/10.1016\/j.coviro.2012.01.008.","DOI":"10.1016\/j.coviro.2012.01.008"},{"key":"10.1016\/j.vaccine.2019.04.011_b0075","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0022-3476(81)80829-3","article-title":"Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level","volume":"98","author":"Glezen","year":"1981","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2019.04.011_b0080","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiy477","article-title":"Breast milk prefusion F IgG as a correlate of protection against respiratory syncytial virus acute respiratory illness","author":"Mazur","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.011_b0085","doi-asserted-by":"crossref","first-page":"e8088","DOI":"10.1371\/journal.pone.0008088","article-title":"The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya","volume":"4","author":"Ochola","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.04.011_b0090","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/jmv.1890070403","article-title":"Maternal antibody and respiratory syncytial virus infection in infancy","volume":"7","author":"Ogilvie","year":"1981","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2019.04.011_b0095","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1016\/S0264-410X(03)00355-4","article-title":"Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies","volume":"21","author":"Piedra","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.011_b0100","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1093\/cid\/ciw559","article-title":"Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction","volume":"63","author":"Amirthalingam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.011_b0105","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002959.pub3","article-title":"Vaccines for women to prevent neonatal tetanus","author":"Demicheli","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2019.04.011_b0110","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1016\/j.vaccine.2015.08.036","article-title":"A global perspective of maternal influenza immunization","volume":"33","author":"Lambach","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.011_b0115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/rmv.1704","article-title":"Respiratory syncytial virus infection and immunity","volume":"22","author":"Gonzalez","year":"2012","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2019.04.011_b0120","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2019.04.011_b0125","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1073\/pnas.1106536108","article-title":"Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers","volume":"108","author":"Swanson","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.04.011_b0130","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/infdis\/jiy065","article-title":"Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: results from 2 phase 2 trials","volume":"217","author":"Beran","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.011_b0135","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database","volume":"27","author":"Pellegrini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.011_b0140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/infdis\/jiw453","article-title":"A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant","volume":"215","author":"Langley","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.011_b0145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/infdis\/jiv406","article-title":"A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant Fusion (F) nanoparticle vaccine in healthy women of childbearing age","volume":"213","author":"Glenn","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.011_b0150","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3389\/fimmu.2017.01872","article-title":"Age and influenza-specific pre-vaccination antibodies strongly affect influenza vaccine responses in the Icelandic population whereas disease and medication have small effects","volume":"8","author":"Olafsdottir","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.04.011_b0155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1084\/jem.20120150","article-title":"Germinal center B cells govern their own fate via antibody feedback","volume":"210","author":"Zhang","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.04.011_b0160","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.vaccine.2012.11.009","article-title":"Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine","volume":"31","author":"Glenn","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.011_b0165","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/infdis\/jix489","article-title":"Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection","volume":"216","author":"Capella","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.011_b0170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.04.011_b0175","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1128\/JVI.00235-16","article-title":"Characterization of epitope-specific anti-respiratory syncytial virus (anti-RSV) antibody responses after natural infection and after vaccination with formalin-inactivated RSV","volume":"90","author":"Widjaja","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.011_b0180","article-title":"Epitope-specific serological assays for RSV: conformation matters","volume":"7","author":"Phung","year":"2019","journal-title":"Vaccines (Basel)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:31:49Z","timestamp":1759401109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19304499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":36,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19304499"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}